{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:18:11Z","timestamp":1792786691603,"version":"4.5.0"},"reference-count":326,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institute of Pharmaceutical Education and Research"},{"name":"University Institute of Pharmacy"},{"name":"Pt. Ravishankar Shukla University","id":[{"id":"https:\/\/ror.org\/0481cg432","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Cell of Chhattisgarh Swami Vivekanand Technical University","id":[{"id":"https:\/\/ror.org\/02wdfg707","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jconrel.2020.02.020","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T08:29:04Z","timestamp":1581496144000},"page":"372-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":224,"special_numbering":"C","title":["Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting"],"prefix":"10.1016","volume":"321","author":[{"given":"Mukta","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0368-5917","authenticated-orcid":false,"given":"Swarnlata","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Kumar","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-6583","authenticated-orcid":false,"given":"Anu","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravish J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ajazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ravichandiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upadhyayula Suryanarayana","family":"Murty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-7650","authenticated-orcid":false,"given":"Amit","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.02.020_bb0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","article-title":"Potential of solid lipid nanoparticles in brain targeting","volume":"127","author":"Kaur","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0010","first-page":"21","article-title":"The cerebrospinal fluid and barriers - anatomic and physiologic considerations","volume":"146","author":"Tumani","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cis.2017.12.002","article-title":"Nanotherapy for Alzheimer\u2019s disease and vascular dementia: targeting senile endothelium","volume":"251","author":"D\u2019Arrigo","year":"2018","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0025","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0030","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1016\/j.biomaterials.2007.06.011","article-title":"Active targeting of brain tumors using nanocarriers","volume":"28","author":"Beduneau","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0035","series-title":"Nanomedicine and The Nervous System","author":"M.L.B.a.E.F. Craparo","year":"2012"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0040","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.2147\/DDDT.S142337","article-title":"The new era of nanotechnology, an alternative to change cancer treatment","volume":"11","author":"Jurj","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/med.20201","article-title":"Nanoparticulate devices for brain drug delivery","volume":"31","author":"Celia","year":"2011","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.drudis.2011.02.006","article-title":"Supramolecular devices to improve the treatment of brain diseases","volume":"16","author":"Paolino","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0021-9797(68)90272-5","article-title":"Controlled growth of monodisperse silica spheres in the micron size range","volume":"26","author":"St\u00f6ber","year":"1968","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cis.2017.06.012","article-title":"Impact of albumin based approaches in nanomedicine: imaging, targeting and drug delivery","volume":"246","author":"Bhushan","year":"2017","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2018.10.004","article-title":"Recent progress of drug nanoformulations targeting to brain","volume":"291","author":"Khan","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0070","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1016\/j.biomaterials.2010.05.060","article-title":"Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs","volume":"31","author":"Licciardi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0075","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1016\/j.biomaterials.2014.04.088","article-title":"Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes","volume":"35","author":"Paolino","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0080","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/adhm.201400738","article-title":"Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response","volume":"4","author":"Kirui","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood-brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.08.008","article-title":"Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?","volume":"71","author":"Kreuter","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0100","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0105","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/nnm.10.107","article-title":"Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances","volume":"5","author":"Buse","year":"2010","journal-title":"Nanomedicine (London, England)"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2016.02.014","article-title":"Nanotoxicology ten years later: lights and shadows","volume":"299","author":"Shvedova","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"7","key":"10.1016\/j.jconrel.2020.02.020_bb0115","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","article-title":"Nanoparticles: properties, applications and toxicities","volume":"12","author":"Khan","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/nnm-2017-0270","article-title":"The inflammatory response to silver and titanium dioxide nanoparticles in the central nervous system","volume":"13","author":"Wu","year":"2018","journal-title":"Nanomedicine (London, England)"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0125","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1289\/ehp.9030","article-title":"Translocation of inhaled ultrafine manganese oxide particles to the central nervous system","volume":"114","author":"Elder","year":"2006","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1155\/2013\/238428","article-title":"Nanoparticles for brain drug delivery","volume":"2013","author":"Masserini","year":"2013","journal-title":"ISRN Biochem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0135","series-title":"Brain Targeted Drug Delivery System","first-page":"219","article-title":"10 - Nanoparticle systems for nose-to-brain delivery","author":"Liu","year":"2019"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cis.2018.08.007","article-title":"Lipid nanocarriers for the loading of polyphenols \u2013 a comprehensive review","volume":"260","author":"Pimentel-Moral","year":"2018","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cis.2017.04.006","article-title":"Advances in structural design of lipid-based nanoparticle carriers for delivery of macromolecular drugs, phytochemicals and anti-tumor agents","volume":"249","author":"Angelova","year":"2017","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0150","first-page":"533","article-title":"Crosslinked biodegradable alginate hydrogel floating beads for stomach site specific controlled delivery of metronidazole","volume":"61","author":"Giri","year":"2013","journal-title":"Farmacia"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.colsurfb.2015.12.033","article-title":"Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique","volume":"140","author":"Becker Peres","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0160","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/jphp.12280","article-title":"Luteolin-phospholipid complex: preparation, characterization and biological evaluation","volume":"66","author":"Khan","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1208\/s12249-010-9563-0","article-title":"Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery","volume":"12","author":"Das","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0170","series-title":"Solid Lipid Nanoparticles (SLN'S) -Trends and Implications in Drug Targeting","author":"Sinha","year":"2010"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0175","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0185","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/156802609787521571","article-title":"Recent advances in medicinal chemistry and pharmaceutical technology\u2014strategies for drug delivery to the brain","volume":"9","author":"Denora","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0190","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1755-5949.2010.00199.x","article-title":"Nanoparticulate systems for drug delivery and targeting to the central nervous system","volume":"17","author":"Craparo","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0195","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.phrs.2010.02.004","article-title":"Nano-interventions for neurodegenerative disorders","volume":"62","author":"Fernandes","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0205","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2009.11.018","article-title":"Non-polymeric nano-carriers in HIV\/AIDS drug delivery and targeting","volume":"62","author":"Gupta","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv. Pharma. Bull."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejps.2012.05.010","article-title":"Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?","volume":"47","author":"Das","year":"2012","journal-title":"Eur. J. Pharma. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0220","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.addr.2007.04.012","article-title":"Nanostructured lipid carriers (NLC) in cosmetic dermal products","volume":"59","author":"M\u00fcller","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0225","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2147\/IJN.S57565","article-title":"Formulation and delivery of itraconazole to the brain using a nanolipid carrier system","volume":"9","author":"Lim","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0230","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","article-title":"Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic","volume":"26","author":"Puri","year":"2009","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0235","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijbiomac.2016.01.014","article-title":"Synthesis and characterisation of poly(acryalamide) grafted carboxymethyl xanthan gum copolymer","volume":"85","author":"Badwaik","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.trac.2015.12.016","article-title":"Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems","volume":"77","author":"Dolatabadi","year":"2016","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0245","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cis.2018.09.002","article-title":"Recent progress in the engineering of multifunctional colloidal nanoparticles for enhanced photodynamic therapy and bioimaging","volume":"261","author":"Lamch","year":"2018","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0250","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/03639040903264397","article-title":"Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers","volume":"36","author":"Li","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0255","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/17425247.2014.945416","article-title":"Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy","volume":"12","author":"Alam","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0260","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0265","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0378-5173(95)04286-5","article-title":"Crystallization tendency and polymorphic transitions in triglyceride nanoparticles","volume":"129","author":"Bunjes","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0270","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1166\/jbn.2013.1490","article-title":"Lipid nanocarriers containing ester prodrugs of flurbiprofen preparation, physical-chemical characterization and biological studies","volume":"9","author":"Bondil","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0275","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/17425240903362410","article-title":"Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art","volume":"7","author":"Bondi","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0280","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/157341309788921516","article-title":"Lipid matrix nanoparticles: pharmacokinetics and biopharmaceutics","volume":"5","author":"Doktorovova","year":"2009","journal-title":"Curr. Nanosci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0285","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2007.04.007","article-title":"Solid lipid nanoparticles as a drug delivery system for peptides and proteins","volume":"59","author":"Almeida","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0290","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.addr.2007.04.006","article-title":"Lipid nanoparticles for improved topical application of drugs for skin diseases","volume":"59","author":"Sch\u00e4fer-Korting","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0168-3659(94)90047-7","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization","volume":"30","author":"Schwarz","year":"1994","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0305","first-page":"211","article-title":"Production of solid lipid nanoparticles-drug loading and release mechanism","volume":"2","author":"Parhi","year":"2010","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0310","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0001-8686(98)00063-3","article-title":"Structure, dynamics and transport properties of microemulsions","volume":"78","author":"Moulik","year":"1998","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijpharm.2007.05.060","article-title":"Nanostructured lipid carrier (NLC) based gel of celecoxib","volume":"346","author":"Joshi","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0320","series-title":"Method for Producing Solid Lipid Microspheres Having a Narrow Size Distribution","author":"Gasco","year":"1993"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0325","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.colsurfa.2007.04.067","article-title":"Production of drug-loaded lipid nanoparticles based on phase behaviors of special hot microemulsions","volume":"313","author":"Xia","year":"2008","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0330","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s11051-010-9998-y","article-title":"Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion\/solvent evaporation method","volume":"13","author":"Liu","year":"2011","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0335","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijpharm.2013.03.034","article-title":"Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization","volume":"454","author":"Shete","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0340","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.colsurfb.2005.08.005","article-title":"Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system","volume":"45","author":"Hu","year":"2005","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0345","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/03639040701662230","article-title":"Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers","volume":"34","author":"Liu","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0350","first-page":"23","article-title":"Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers","volume":"19","author":"Thatipamula","year":"2011","journal-title":"Daru"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0355","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.colsurfb.2013.08.032","article-title":"Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro","volume":"113","author":"Sun","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0360","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0168-3659(01)00354-6","article-title":"Lipid microparticles as a parenteral controlled release device for peptides","volume":"73","author":"Reithmeier","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0365","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2015.11.032","article-title":"Revisiting nanoparticle technology for blood-brain barrier transport: unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes","volume":"222","author":"Johnsen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0370","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0375","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","article-title":"Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment","volume":"145","author":"Loureiro","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0385","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/sj.jcbfm.9600521","article-title":"Supply and demand in cerebral energy metabolism: the role of nutrient transporters","volume":"27","author":"Simpson","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6336(88)80001-9","article-title":"Ultrastructural cytochemistry of blood-brain barrier endothelia","volume":"18","author":"Vorbrodt","year":"1988","journal-title":"Prog. Histochem. Cytochem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0395","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/sj.jcbfm.9600278","article-title":"Estradiol reduces activity of the blood-brain barrier Na-K-Cl cotransporter and decreases edema formation in permanent middle cerebral artery occlusion","volume":"26","author":"O'Donnell","year":"2006","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0400","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"Loscher","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tips.2007.01.007","article-title":"Implications of ATP-binding cassette transporters for brain pharmacotherapies","volume":"28","author":"Hermann","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0410","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nri2852","article-title":"The impact of the extracellular matrix on inflammation","volume":"10","author":"Sorokin","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0415","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","article-title":"The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction","volume":"31","author":"Engelhardt","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0420","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/17425240902939143","article-title":"The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier","volume":"6","author":"Barbu","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0425","first-page":"1","article-title":"Advances in brain targeted drug delivery: nanoparticulate systems","volume":"3","author":"Joseph","year":"2013","journal-title":"J. PharmaSciTech"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0430","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3329\/sjps.v4i1.8878","article-title":"Polymers and permeation enhancers: specialized components of mucoadhesives","volume":"4","author":"Alexander","year":"2011","journal-title":"Stanford J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0435","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0440","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2004.07.006","article-title":"Paclitaxel nanoparticles for the potential treatment of brain tumors","volume":"99","author":"Koziara","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0445","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1016\/j.biomaterials.2007.05.014","article-title":"Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments","volume":"28","author":"Beduneau","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0450","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2007.11.001","article-title":"Brain targeting using novel lipid nanovectors","volume":"126","author":"Beduneau","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0455","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.xphs.2018.04.007","article-title":"Superparamagnetic iron oxide-loaded lipid nanocarriers incorporated in thermosensitive in situ gel for magnetic brain targeting of clonazepam","volume":"107","author":"Abbas","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0460","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijpharm.2014.07.025","article-title":"Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route","volume":"473","author":"Gabal","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0465","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.xphs.2017.08.024","article-title":"Nose to brain delivery of Rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics","volume":"106","author":"Wavikar","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0470","article-title":"Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting","volume":"23","author":"Liu","year":"2012","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0475","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.msec.2018.02.004","article-title":"Design of lactoferrin modified lipid nano-carriers for efficient brain-targeted delivery of nimodipine","volume":"92","author":"Zhao","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0480","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0485","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejps.2017.02.032","article-title":"Nose-to-brain transport of imatinib mesylate: a pharmacokinetic evaluation","volume":"102","author":"Hada","year":"2017","journal-title":"Eur. J. Pharma. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0490","first-page":"2088","article-title":"Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting","volume":"46","author":"Selvaraj","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0495","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/14712598.3.3.519","article-title":"Nasal drug delivery","volume":"3","author":"Suman","year":"2003","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0500","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2174\/138920112803341752","article-title":"Drug delivery systems from nose to brain","volume":"13","author":"Misra","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0505","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"issue":"Suppl. 3","key":"10.1016\/j.jconrel.2020.02.020_bb0510","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharma. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0520","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0525","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","article-title":"Nose-to-brain peptide delivery - the potential of nanotechnology","volume":"26","author":"Samaridou","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0530","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jat.3213","article-title":"In vitro cytotoxicity of superparamagnetic iron oxide nanoparticles on neuronal and glial cells. Evaluation of nanoparticle interference with viability tests","volume":"36","author":"Costa","year":"2016","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0535","doi-asserted-by":"crossref","first-page":"8501693","DOI":"10.1155\/2016\/8501693","article-title":"Current research therapeutic strategies for Alzheimer\u2019s disease treatment","volume":"2016","author":"Folch","year":"2016","journal-title":"Neural Plast."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0540","series-title":"Alzheimer\u2019s Disease International","first-page":"140","article-title":"World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future","author":"Prince","year":"2016"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0545","series-title":"Alzheimer's & Dementia","first-page":"321","article-title":"2019 Alzheimer's disease facts and figures","volume":"15","year":"2019"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0550","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17425247.2018.1471058","article-title":"Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region","volume":"15","author":"Agrawal","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0555","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/17425247.2013.762354","article-title":"Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB","volume":"10","author":"Nagpal","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0560","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","article-title":"Delivery of therapeutic agents to the central nervous system: the problems and the possibilities","volume":"104","author":"Begley","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0565","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","article-title":"Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease","volume":"260","author":"Agrawal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0570","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/03639045.2019.1593439","article-title":"Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer\u2019s disease using box-Behnken design","volume":"45","author":"Jojo","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0575","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0580","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jddst.2018.11.021","article-title":"Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model","volume":"49","author":"Anand","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0585","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/08982104.2014.954129","article-title":"Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery","volume":"25","author":"Wavikar","year":"2015","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0590","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1208\/s12249-013-9986-5","article-title":"Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity","volume":"14","author":"Kumbhar","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0595","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1208\/s12249-012-9908-y","article-title":"Nanolipidgel for enhanced skin deposition and improved antifungal activity","volume":"14","author":"Wavikar","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0600","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2015.06.001","article-title":"Recent approaches for reducing hemolytic activity of chemotherapeutic agents","volume":"211","author":"Jeswani","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0605","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0925-4439(96)00032-4","article-title":"Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells","volume":"1317","author":"Kuo","year":"1996","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0610","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.colsurfb.2013.06.032","article-title":"Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability","volume":"111","author":"Sun","year":"2013","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0615","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.nano.2012.11.004","article-title":"Curcumin-conjugated nanoliposomes with high affinity for A\u03b2 deposits: possible applications to Alzheimer disease","volume":"9","author":"Lazar","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0620","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/acschemneuro.8b00510","article-title":"Brain delivery of curcumin using solid lipid nanoparticles and nanostructured lipid carriers: preparation, optimization, and pharmacokinetic evaluation","volume":"10","author":"Sadegh Malvajerd","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0625","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3233\/JAD-190083","article-title":"Neuroprotective potential of curcumin-loaded nanostructured lipid carrier in an animal model of Alzheimer\u2019s disease: behavioral and biochemical evidence","volume":"69","author":"Sadegh Malvajerd","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0630","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/21655979.2016.1197029","article-title":"Comparative analysis of protective effects of curcumin, curcumin-beta-cyclodextrin nanoparticle and nanoliposomal curcumin on unsymmetrical dimethyl hydrazine poisoning in mice","volume":"7","author":"Li","year":"2016","journal-title":"Bioengineered"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0635","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1208\/s12249-013-0023-5","article-title":"Molecular inclusion complex of curcumin-beta-cyclodextrin nanoparticle to enhance curcumin skin permeability from hydrophilic matrix gel","volume":"14","author":"Rachmawati","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0640","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2016.04.033","article-title":"Design and evaluation of lipoprotein resembling curcumin-encapsulated protein-free nanostructured lipid carrier for brain targeting","volume":"506","author":"Meng","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0645","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","article-title":"Nanoparticulate systems for brain delivery of drugs","volume":"47","author":"Kreuter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0650","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028881","article-title":"A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain","volume":"6","author":"Sarkar","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0660","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.colsurfb.2015.06.025","article-title":"A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease","volume":"134","author":"Meng","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0665","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.2147\/IJN.S36257","article-title":"In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration","volume":"7","author":"Fang","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0670","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/biof.118","article-title":"Neuroprotective properties of resveratrol in different neurodegenerative disorders","volume":"36","author":"Albani","year":"2010","journal-title":"BioFactors (Oxford, England)"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0675","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1016\/j.biomaterials.2013.05.035","article-title":"The effect of resveratrol on neurodegeneration and blood brain barrier stability surrounding intracortical microelectrodes","volume":"34","author":"Potter","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0680","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/187152807781696464","article-title":"Anti-inflammatory responses of resveratrol","volume":"6","author":"Das","year":"2007","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0685","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.bbrc.2003.08.105","article-title":"Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses","volume":"309","author":"Leonard","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0690","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12951-016-0177-x","article-title":"Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E","volume":"14","author":"Neves","year":"2016","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0695","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejpb.2018.02.010","article-title":"Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles","volume":"127","author":"Trotta","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0700","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2017.09.043","article-title":"The present and future of pharmacotherapy of Alzheimer\u2019s disease: a comprehensive review","volume":"815","author":"Anand","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0705","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1021\/bm801178f","article-title":"Effect of poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles","volume":"10","author":"Gaucher","year":"2009","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0710","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jnutbio.2013.10.002","article-title":"Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals","volume":"25","author":"Wang","year":"2014","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0715","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijpharm.2016.10.024","article-title":"Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: biochemical, pharmacokinetic and biodistribution evidences","volume":"515","author":"Kumar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0720","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ane.12386","article-title":"Donepezil across the spectrum of Alzheimer\u2019s disease: dose optimization and clinical relevance","volume":"131","author":"Lee","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0725","series-title":"The Cochrane Database of Systematic Reviews","article-title":"Donepezil for dementia due to Alzheimer's disease","author":"Birks","year":"2006"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0730","doi-asserted-by":"crossref","first-page":"P299","DOI":"10.1016\/j.jalz.2013.05.609","article-title":"Curcumin-donepezil\u2013loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer\u2019s disease model","volume":"9","author":"Sood","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0735","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","article-title":"Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration","volume":"134","author":"Gartziandia","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0740","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/10837450.2011.614250","article-title":"Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion","volume":"18","author":"Severino","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0745","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2008.07.034","article-title":"Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation","volume":"131","author":"Dharmala","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0750","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cis.2018.11.008","article-title":"Pharmaceutical applications of chitosan","volume":"263","author":"Shariatinia","year":"2019","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0755","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3109\/03639045.2015.1011167","article-title":"A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates","volume":"41","author":"Alexander","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0760","doi-asserted-by":"crossref","first-page":"31192","DOI":"10.1074\/jbc.M303938200","article-title":"Studies on the internalization mechanism of cationic cell-penetrating peptides","volume":"278","author":"Drin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0765","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/1567201813666160204114000","article-title":"Understanding the role of poloxamer 407 based thermoreversible in situ gelling hydrogel for delivery of PEGylated melphalan conjugate","volume":"13","author":"Alexander","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0770","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1005568132027","article-title":"Interactions between ascorbyl free radical and coenzyme Q at the plasma membrane","volume":"32","author":"Arroyo","year":"2000","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0775","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1073\/pnas.87.12.4879","article-title":"Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations","volume":"87","author":"Frei","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0780","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1166\/jbn.2013.1560","article-title":"Formulation and characterization of nanostructured lipid carrier of ubiquinone (Coenzyme Q10)","volume":"9","author":"Nanjwade","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0785","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2013.02.014","article-title":"Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A","volume":"446","author":"Patel","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0790","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2147\/IJN.S60938","article-title":"Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion","volume":"9","author":"Ding","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0795","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0091-3057(03)00111-4","article-title":"The psychopharmacology of huperzine a: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer\u2019s disease","volume":"75","author":"Zangara","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0800","article-title":"Huperzine A for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0805","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00702-009-0189-x","article-title":"Efficacy and safety of natural acetylcholinesterase inhibitor huperzine a in the treatment of Alzheimer\u2019s disease: an updated meta-analysis","volume":"116","author":"Wang","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0810","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2006.09.001","article-title":"Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design","volume":"66","author":"Chopra","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0815","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1248\/cpb.58.656","article-title":"Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers","volume":"58","author":"Yang","year":"2010","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0820","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2010.01.012","article-title":"Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer\u2019s disease","volume":"389","author":"Smith","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0825","first-page":"134","article-title":"Design and development of resveratrol NLCs and their role in synaptic transmission of acetylcholine in C. elegans model","volume":"12","author":"Anubhav","year":"2017","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0830","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12035-017-0728-7","article-title":"Intranasal administration of TAT-conjugated lipid Nanocarriers loading GDNF for Parkinson\u2019s disease","volume":"55","author":"Hernando","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0835","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","article-title":"Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"348","author":"Nussbaum","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0840","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","article-title":"Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: a mini review","volume":"23","author":"Kulkarni","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0845","first-page":"183","article-title":"Parkinson\u2019s disease: from brain homogenate to treatment","volume":"32","author":"Hornykiewicz","year":"1973","journal-title":"Fed. Proc."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0850","first-page":"1","article-title":"Improved brain pharmacokinetics following intranasal administration of N,N,N-trimethyl chitosan tailored mucoadhesive NLCs","author":"Pardeshi","year":"2019","journal-title":"Mater. Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0855","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fncel.2012.00044","article-title":"Translocating the blood-brain barrier using electrostatics","volume":"6","author":"Ribeiro","year":"2012","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0860","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/17425247.5.2.155","article-title":"Polymeric nanoparticles for the drug delivery to the central nervous system","volume":"5","author":"Tosi","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0865","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.colsurfa.2010.09.030","article-title":"Surfactant effects on the physical characteristics of amphotericin B-containing nanostructured lipid carriers","volume":"372","author":"Tan","year":"2010","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0870","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nano.2008.08.003","article-title":"Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery","volume":"5","author":"Paliwal","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0875","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijpharm.2006.11.056","article-title":"Intrapericardial administration of novel DNA formulations based on thermosensitive Poloxamer 407 gel","volume":"331","author":"Roques","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0880","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1166\/jbn.2016.2313","article-title":"Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson\u2019s disease","volume":"12","author":"Gartziandia","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0885","first-page":"2677","article-title":"Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson\u2019s disease","volume":"9","author":"Herran","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0890","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/00063030-200519020-00003","article-title":"Therapeutic potential of neurotrophic factors in neurodegenerative diseases","volume":"19","author":"Levy","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0895","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/03639045.2013.789051","article-title":"Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery","volume":"40","author":"Sharma","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0900","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3109\/03639045.2014.991400","article-title":"Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting","volume":"41","author":"Jafarieh","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0905","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2011.09.008","article-title":"Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals","volume":"420","author":"Qin","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0910","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","article-title":"Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles","volume":"34","author":"Kanazawa","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0915","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3109\/10717544.2014.975382","article-title":"Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study","volume":"23","author":"Madane","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0920","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00415-010-5793-z","article-title":"A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation","volume":"258","author":"Antonini","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0925","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1023\/B:PHAM.0000026425.69874.8e","article-title":"Characterization and modulation of the transferrin receptor on brain capillary endothelial cells","volume":"21","author":"Visser","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0930","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1007\/s11095-008-9615-2","article-title":"Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line","volume":"25","author":"Chattopadhyay","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0935","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0940","doi-asserted-by":"crossref","first-page":"405101","DOI":"10.1088\/0957-4484\/21\/40\/405101","article-title":"Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug","volume":"21","author":"Hsu","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0945","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41416-018-0029-6","article-title":"The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0950","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.2174\/1389557517666170927112150","article-title":"Theranostic potential of targeted nanoparticles for brain cancer","volume":"17","author":"Bhatt","year":"2017","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0955","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(11)61346-9","article-title":"Primary brain tumours in adults","volume":"379","author":"Ricard","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0960","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1016\/j.xphs.2017.08.009","article-title":"Targeted drug delivery via folate receptors for the treatment of brain cancer: can the promise deliver?","volume":"106","author":"Guo","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0965","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2006.09.012","article-title":"Brain cancer diagnosis and therapy with nanoplatforms","volume":"58","author":"Koo","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0970","doi-asserted-by":"crossref","DOI":"10.18433\/jpps30117","article-title":"Targeted nanostructured lipid carrier for brain delivery of artemisinin: design, preparation, characterization, optimization and cell toxicity","volume":"21","author":"Emami","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0975","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpb.2007.01.015","article-title":"Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - development, physicochemical characterization and in vitro release studies","volume":"67","author":"Teeranachaideekul","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0980","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10837450.2016.1189933","article-title":"Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using box-Behnken design","volume":"22","author":"Emami","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0985","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jpsychires.2012.05.014","article-title":"Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain","volume":"46","author":"Alam","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb0990","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.colsurfb.2010.06.008","article-title":"Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies","volume":"80","author":"Jia","year":"2010","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb0995","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejps.2009.04.008","article-title":"Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin","volume":"37","author":"Subedi","year":"2009","journal-title":"Eur. J. Pharma. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1000","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2007.05.061","article-title":"Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery","volume":"345","author":"Shah","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1005","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1021\/acs.molpharmaceut.6b00586","article-title":"Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses","volume":"13","author":"Khan","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1010","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1080\/10717544.2016.1189465","article-title":"Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?","volume":"23","author":"Qu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1015","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3109\/10717544.2015.1064186","article-title":"Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy","volume":"23","author":"Song","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.nano.2011.02.007","article-title":"Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake","volume":"7","author":"Bothun","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1025","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3109\/10717544.2015.1058434","article-title":"Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery","volume":"23","author":"Wu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1030","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3109\/10717544.2015.1038857","article-title":"Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy","volume":"23","author":"Chen","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1035","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3109\/10717544.2015.1049719","article-title":"Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo","volume":"23","author":"Chen","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1040","first-page":"363","article-title":"Anticancer potential of curcumin: preclinical and clinical studies","volume":"23","author":"Aggarwal","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1045","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/jps.22113","article-title":"Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies","volume":"99","author":"Zhao","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1055","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1166\/jnn.2011.4235","article-title":"Development and evaluation of nanostructured lipid carriers of cytarabine for treatment of meningeal leukemia","volume":"11","author":"Sharma","year":"2011","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1060","first-page":"54","article-title":"Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine","volume":"28","author":"Capizzi","year":"1991","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1065","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/1042819032000159861","article-title":"Problems related to resistance to cytarabine in acute myeloid leukemia","volume":"45","author":"Cros","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1070","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1211\/jpp.61.11.0007","article-title":"Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers","volume":"61","author":"Li","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1075","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.plefa.2006.02.002","article-title":"Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls","volume":"74","author":"Nilsson","year":"2006","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/schbul\/sbn151","article-title":"Physical manifestations of neurodevelopmental disruption: are minor physical anomalies part of the syndrome of schizophrenia?","volume":"35","author":"Compton","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1085","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.psyneuen.2012.09.009","article-title":"Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies","volume":"38","author":"Harris","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1090","series-title":"World Health Organization","article-title":"Schizophrenia","author":"WHO","year":"2018"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081689","article-title":"New targets for schizophrenia treatment beyond the dopamine hypothesis","volume":"18","author":"Yang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2016.05.015","article-title":"Treatment of negative symptoms: where do we stand, and where do we go?","volume":"186","author":"Aleman","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1105","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.2174\/138161281941131219123329","article-title":"Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer\u2019s and schizophrenia","volume":"19","author":"Silva","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3371\/CSRP.4.4.5","article-title":"Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic","volume":"4","author":"Citrome","year":"2011","journal-title":"Clin. Schizophr. Relate. Psychoses"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1115","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3109\/03639045.2015.1118496","article-title":"Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state","volume":"42","author":"Miao","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1120","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.pharep.2016.04.002","article-title":"Lurasidone: the 2016 update on the pharmacology, efficacy and safety profile","volume":"68","author":"Jaeschke","year":"2016","journal-title":"Pharmacological Reports: PR"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ddr.21331","article-title":"Delivery of antipsychotics with nanoparticles","volume":"77","author":"Sun","year":"2016","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1130","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.xphs.2019.05.001","article-title":"Optimization of nanostructured lipid carriers of Lurasidone hydrochloride using box-Behnken design for brain targeting: in vitro and in vivo studies","volume":"108","author":"Jazuli","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1135","article-title":"Neutropenia and leukopenia protective intranasal olanzapine-loaded lipid-based nanocarriers engineered for brain delivery","volume":"9","author":"Gadhave","year":"2018","journal-title":"Appl. Nanosci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12249-018-1213-y","article-title":"Agranulocytosis-protective olanzapine-loaded nanostructured lipid carriers engineered for CNS delivery: optimization and hematological toxicity studies","volume":"20","author":"Gadhave","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1145","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1039\/C5RA19793G","article-title":"Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment","volume":"6","author":"Singh","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1150","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.4155\/tde.13.101","article-title":"Assessment of novel iloperidone- and idebenone-loaded nanostructured lipid carriers: brain targeting efficiency and neuroprotective potential","volume":"4","author":"Mandpe","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1155","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/mp300149w","article-title":"Idebenone loaded solid lipid nanoparticles interact with biomembrane models: calorimetric evidence","volume":"9","author":"Montenegro","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1160","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00213-005-0117-1","article-title":"Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia","volume":"182","author":"Dakhale","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0920-9964(02)00284-0","article-title":"Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia","volume":"62","author":"Arvindakshan","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1170","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/jps.2600791009","article-title":"Solubilization of salicylamide and acetaminophen by antihistamines in aqueous solution","volume":"79","author":"Shah","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2009.06.001","article-title":"Lipid\u2014an emerging platform for oral delivery of drugs with poor bioavailability","volume":"73","author":"Chakraborty","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1185","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jps.20480","article-title":"Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting","volume":"95","author":"Vyas","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1190","first-page":"551","article-title":"Multiple sclerosis - etiology and diagnostic potential","volume":"71","author":"Kaminska","year":"2017","journal-title":"Postepy higieny i medycyny doswiadczalnej (Online)"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1195","series-title":"Neurological Disorders: Public Health Challenges","first-page":"85","article-title":"Multiple sclerosis","author":"Douglas","year":"2005"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1200","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WCO.0000000000000206","article-title":"Classification, diagnosis, and differential diagnosis of multiple sclerosis","volume":"28","author":"Katz Sand","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/jnnp-2016-314490","article-title":"Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016","volume":"89","author":"Claflin","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1215","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","article-title":"Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies","volume":"45","author":"Gadhave","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1220","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/acschemneuro.6b00428","article-title":"Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies","volume":"8","author":"Kumar","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jddst.2016.06.012","article-title":"Brain delivery of baclofen as a hydrophilic drug by nanolipid carriers: characteristics and pharmacokinetics evaluation","volume":"37","author":"Ghasemian","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1230","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/10611860400015936","article-title":"Nanoparticle surface charges alter blood-brain barrier integrity and permeability","volume":"12","author":"Lockman","year":"2004","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejpb.2011.02.009","article-title":"Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration","volume":"79","author":"Priano","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1240","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00558228","article-title":"Plasma and urinary excretion kinetics of oral baclofen in healthy subjects","volume":"37","author":"Wuis","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1245","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ndt\/gfh297","article-title":"Treatment of baclofen overdose by haemodialysis: a pharmacokinetic study","volume":"20","author":"Wu","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1250","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archneur.1989.00520420080026","article-title":"Interrater reliability of the NIH stroke scale","volume":"46","author":"Goldstein","year":"1989","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1255","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01376517-200710000-00005","article-title":"Acute ischemic stroke review","volume":"39","author":"Hinkle","year":"2007","journal-title":"J. Neurosci. Nurs."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1260","doi-asserted-by":"crossref","first-page":"118754","DOI":"10.1016\/j.ijpharm.2019.118754","article-title":"Brain targeting of Baicalin and Salvianolic acid B combination by OX26 functionalized nanostructured lipid carriers","volume":"571","author":"Wu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1265","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3109\/10717544.2014.943337","article-title":"Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain","volume":"23","author":"Salunkhe","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ijpharm.2011.12.009","article-title":"Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting","volume":"423","author":"Tsai","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1275","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/IJN.S159789","article-title":"Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo","volume":"13","author":"Yuan","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1280","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijpharm.2014.02.013","article-title":"A novel oral delivery system consisting in \u201cdrug-in cyclodextrin-in nanostructured lipid carriers\u201d for poorly water-soluble drug: vinpocetine","volume":"465","author":"Lin","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1285","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2010.05.005","article-title":"Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability","volume":"394","author":"Zhuang","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brainres.2010.07.098","article-title":"Mismatch between changes in baicalein-induced memory-related biochemical parameters and behavioral consequences in mouse","volume":"1355","author":"Park","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1295","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.brainres.2008.10.005","article-title":"Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage","volume":"1249","author":"He","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1300","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pbb.2011.01.011","article-title":"Baicalein protects the brain against neuron impairments induced by MPTP in C57BL\/6 mice","volume":"98","author":"Mu","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1305","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/sj.bjp.0704959","article-title":"The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study","volume":"137","author":"Tsai","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1310","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.addr.2003.12.005","article-title":"Tocol emulsions for drug solubilization and parenteral delivery","volume":"56","author":"Constantinides","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1315","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2007.12.046","article-title":"Optimization of tocol emulsions for the intravenous delivery of clarithromycin","volume":"356","author":"Li","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2014.10.047","article-title":"In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes","volume":"1594","author":"Candela","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2014.07.014","article-title":"Nifedipine and nimodipine protect dopaminergic substantia nigra neurons against axotomy-induced cell death in rat vibrosections via modulating inflammatory responses","volume":"1581","author":"Daschil","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1330","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00002512-199405020-00007","article-title":"Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders","volume":"5","author":"Gillis","year":"1994","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1335","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(99)00223-0","article-title":"Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties","volume":"66","author":"Jenning","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1340","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022426","article-title":"Seizures and epilepsy: an overview for neuroscientists","volume":"5","author":"Stafstrom","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1345","doi-asserted-by":"crossref","first-page":"a022848","DOI":"10.1101\/cshperspect.a022848","article-title":"Epilepsy: a spectrum disorder","volume":"5","author":"Sirven","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1350","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2017.11.015","article-title":"The new definition and classification of seizures and epilepsy","volume":"139","author":"Falco-Walter","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1355","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0733-8627(20)30386-2","article-title":"Overview of seizures","volume":"12","author":"Engel","year":"1994","journal-title":"Emerg. Med. Clin. North Am."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1360","series-title":"World Health Organization","article-title":"Epilepsy","author":"WHO","year":"2019"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1365","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cis.2017.05.003","article-title":"Iron oxide nanoparticles \u2013 in vivo\/in vitro biomedical applications and in silico studies","volume":"249","author":"Nedyalkova","year":"2017","journal-title":"Adv. Colloid Interf. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2020.02.020_bb1370","first-page":"1","article-title":"Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability","volume":"42","author":"Alvarez","year":"1998","journal-title":"J. Intellect. Disabil. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1375","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1380","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0378-5173(01)00806-7","article-title":"Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations","volume":"228","author":"Puglia","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1385","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejpb.2009.03.003","article-title":"Dexamethasone-containing biodegradable superparamagnetic microparticles for intra-articular administration: physicochemical and magnetic properties, in vitro and in vivo drug release","volume":"72","author":"Butoescu","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1390","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","volume":"7","author":"Arora","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1395","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jphp.12262","article-title":"Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate","volume":"66","author":"Alexander","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1400","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cis.2013.06.007","article-title":"Superparamagnetic iron oxide based nanoprobes for imaging and theranostics","volume":"199\u2013200","author":"Lam","year":"2013","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1405","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/21691401.2016.1160407","article-title":"Development and characterization of embelin-loaded nanolipid carriers for brain targeting","volume":"45","author":"Sharma","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1410","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1073858409354385","article-title":"Is epilepsy a preventable disorder? New evidence from animal models","volume":"16","author":"Giblin","year":"2010","journal-title":"Neuroscientist"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357022539","article-title":"Is nose-to-brain transport of drugs in man a reality?","volume":"56","author":"Illum","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(01)00172-7","article-title":"The nose and paranasal sinuses physiology and anatomy","volume":"51","author":"Jones","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1425","first-page":"363","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1430","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(02)00423-8","article-title":"P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats","volume":"327","author":"Potschka","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1435","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.antiviral.2011.09.012","article-title":"Brain distribution of ribavirin after intranasal administration","volume":"92","author":"Colombo","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1440","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijpharm.2010.06.048","article-title":"Comparison of different absorption enhancers on the intranasal absorption of isosorbide dinitrate in rats","volume":"397","author":"Na","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1445","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/1531-8249(199904)45:4<444::AID-ANA5>3.0.CO;2-6","article-title":"Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy","volume":"45","author":"Vainionpaa","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1450","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10837450903013568","article-title":"Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design","volume":"15","author":"Varshosaz","year":"2010","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1455","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.addr.2007.05.002","article-title":"Lipid nanoparticles: recent advances","volume":"59","author":"M\u00fcller","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1460","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.nano.2014.12.014","article-title":"Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases","volume":"11","author":"Gendelman","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1465","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijpara.2006.02.004","article-title":"Human cerebral malaria and the blood-brain barrier","volume":"36","author":"Medana","year":"2006","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1470","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/02652048.2018.1441915","article-title":"Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers","volume":"35","author":"Vanka","year":"2018","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1475","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ejps.2010.05.007","article-title":"Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: pharmacokinetics, toxicological and in vivo anti-malarial activity","volume":"40","author":"Aditya","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1480","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10717544.2014.885999","article-title":"Optimization of artemether-loaded NLC for intranasal delivery using central composite design","volume":"22","author":"Jain","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1485","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1208\/s12249-011-9614-1","article-title":"Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution","volume":"12","author":"Hoekman","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1490","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jac\/dkn112","article-title":"Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children","volume":"61","author":"Wintergerst","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1495","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2005.10.042","article-title":"Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol ATO 5","volume":"309","author":"Jannin","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1500","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biopha.2017.07.067","article-title":"Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: in-vivo pharmacokinetic and toxicity study","volume":"94","author":"Pokharkar","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1505","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110446","article-title":"Development of nose-to-brain delivery of ketoconazole by nanostructured lipid carriers against cryptococcal meningoencephalitis in mice","volume":"183","author":"Du","year":"2019","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1510","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.colsurfb.2014.06.037","article-title":"Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer","volume":"122","author":"Devkar","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1515","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10717544.2013.822945","article-title":"Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood","volume":"20","author":"Alam","year":"2013","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2014.05.004","article-title":"Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug","volume":"470","author":"Alam","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1525","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08982104.2010.539186","article-title":"Evaluation of the in vitro differential protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (NLCs) for potential targeting to the brain","volume":"21","author":"Kasongo","year":"2011","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1530","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2008.05.039","article-title":"Development and evaluation of novel itraconazole-loaded intravenous nanoparticles","volume":"362","author":"Chen","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1535","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1540","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0939-6411(03)00063-8","article-title":"Intravenous itraconazole emulsions produced by SolEmuls technology","volume":"56","author":"Akkar","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1545","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2009.09.008","article-title":"Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release","volume":"383","author":"Kim","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1550","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.powtec.2011.12.063","article-title":"RETRACTED: ondansetron loaded pectin based microspheres for nasal administration: in vitro and in vivo studies","volume":"221","author":"Mahajan","year":"2012","journal-title":"Powder Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1555","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/10837450802712625","article-title":"Development and evaluation of pulsatile drug delivery system using novel polymer","volume":"14","author":"Tekade","year":"2009","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1560","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s10856-012-4702-7","article-title":"Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation","volume":"23","author":"Joshi","year":"2012","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1565","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","article-title":"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model","volume":"48","author":"Md","year":"2013","journal-title":"Eur. J. Pharma. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1570","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3956(02)00060-2","article-title":"Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression","volume":"36","author":"Detke","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1575","first-page":"252","article-title":"Drug delivery to the central nervous system: a review","volume":"6","author":"Misra","year":"2003","journal-title":"J. Pharma Pharma. Sci."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1580","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/mp800032f","article-title":"Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution","volume":"5","author":"Dobrovolskaia","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1585","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0169-409X(95)00039-A","article-title":"Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system","volume":"17","author":"Storm","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1590","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-5173(00)00639-6","article-title":"The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles","volume":"214","author":"Gessner","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1595","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10611860500071292","article-title":"Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns","volume":"13","author":"Goppert","year":"2005","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1600","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(99)00025-3","article-title":"Improved uptake and retention of lipophilic prodrug to improve treatment of HIV","volume":"39","author":"Yatvin","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1605","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1476-511X-11-159","article-title":"Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy","volume":"11","author":"Selvamuthukumar","year":"2012","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jconrel.2020.02.020_bb1610","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.colsurfb.2013.12.012","article-title":"Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride","volume":"116","author":"Ranpise","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2020.02.020_bb1611","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.2147\/IJN.S210876","article-title":"Recent expansions of novel strategies towards the drug targeting into the brain","volume":"14","author":"Alexander","year":"2019","journal-title":"International Journal of Nanomedicine"},{"issue":"12","key":"10.1016\/j.jconrel.2020.02.020_bb1612","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4103\/1673-5374.241458","article-title":"Nose-to-brain drug delivery approach: A key to easily accessing the brain for the treatment of Alzheimer\u2019s disease","volume":"13","author":"Alexander","year":"2018","journal-title":"Neural Regeneration Research"},{"issue":"10","key":"10.1016\/j.jconrel.2020.02.020_bb1613","first-page":"4538","article-title":"Gupta UJMp. Boosted Memory and Improved Brain Bioavailability of Rivastigmine: Targeting Effort to the Brain Using Covalently Tethered Lower Generation PAMAM Dendrimers with","volume":"15","author":"Gothwal","year":"2018","journal-title":"Lactoferrin"},{"issue":"2","key":"10.1016\/j.jconrel.2020.02.020_bb1614","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10571-019-00653-z","article-title":"Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer\u2019s Disease","volume":"39","author":"Dubey","year":"2019","journal-title":"Cellular and Molecular Neurobiology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920301097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920301097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:50:18Z","timestamp":1759161018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920301097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":326,"alternative-id":["S0168365920301097"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.02.020","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}